NICE updates COVID-19 rapid guidelines on dialysis, cystic fibrosis, and managing symptoms including at the end of life

NICE has updated a series of COVID-19 rapid guidelines. The updated guidelines are as follows:

The COVID-19 rapid guideline on dialysis was updated on 11 September 2020 to clarify guidance for organisations on planned procedures and emergency pathways for creating dialysis access sites for patients with advanced or end-stage kidney disease.

Regarding the COVID-19 rapid guidance on cystic fibrosis, on 7 October 2020, NICE withdrew recommendations on reducing or deprioritising cystic fibrosis registry data entry, limiting transplant services, and deferring transition to adult services because these emergency measures are no longer needed.

On 13 October 2020, NICE updated the COVID-19 rapid guideline on managing symptoms (including at the end of life) by amending recommendations on taking patients’ existing medicines into account with reference to MHRA advice on warfarin and other anticoagulants—monitoring of patients during the COVID-19 pandemic, which includes reports of supratherapeutic anticoagulation with warfarin.